Abstract
Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 865-881 |
| Number of pages | 17 |
| Journal | American Journal of Obstetrics and Gynecology |
| Volume | 145 |
| Issue number | 7 |
| State | Published - Apr 1 1983 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
- Obstetrics and Gynecology
Cite this
Metronidazole use in obstetrics and gynecology : A review. / Robbie, Marilyn Olson; Sweet, Richard L.
In: American Journal of Obstetrics and Gynecology, Vol. 145, No. 7, 01.04.1983, p. 865-881.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metronidazole use in obstetrics and gynecology
T2 - A review
AU - Robbie, Marilyn Olson
AU - Sweet, Richard L
PY - 1983/4/1
Y1 - 1983/4/1
N2 - Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.
AB - Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.
UR - http://www.scopus.com/inward/record.url?scp=0020646991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020646991&partnerID=8YFLogxK
M3 - Article
C2 - 6340508
AN - SCOPUS:0020646991
VL - 145
SP - 865
EP - 881
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
SN - 0002-9378
IS - 7
ER -